![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cost-effectiveness of Combination Daclatasvir-Sofosbuvirfor
Genotype 3 Chronic Hepatitis C Infection in the United States
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Catherine Saint-Laurent Thibault,1DivyaMoorjaney,2Michael L. Ganz,2Bruce Sill,3ShaliniHede,3Yong Yuan,3AnupamaKalsekar,3Boris Gorsh3
1Evidera, Montreal, QC, Canada; 2Evidera, Lexington, MA, USA; 3Bristol-Myers Squibb Company, Plainsboro, NJ, USA
![AASLD1.gif](../images/120315/120315-7/AASLD1.gif)
![AASLD2.gif](../images/120315/120315-7/AASLD2.gif)
![AASLD3.gif](../images/120315/120315-7/AASLD3.gif)
![AASLD4.gif](../images/120315/120315-7/AASLD4.gif)
![AASLD5.gif](../images/120315/120315-7/AASLD5.gif)
![AASLD6.gif](../images/120315/120315-7/AASLD6.gif)
![AASLD7.gif](../images/120315/120315-7/AASLD7.gif)
![AASLD8.gif](../images/120315/120315-7/AASLD8.gif)
![AASLD9.gif](../images/120315/120315-7/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|